Referências
Principais artigos
Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Apr 1;27(4):387-413.Texto completo Resumo
Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug;22(8):1342-56.Texto completo Resumo
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Texto completo Resumo
McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Texto completo Resumo
McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6. Resumo
National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. Sep 2018 [internet publication].Texto completo
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Texto completo Resumo
Artigos de referência
1. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Apr 1;27(4):387-413.Texto completo Resumo
2. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug;22(8):1342-56.Texto completo Resumo
3. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-87.Texto completo Resumo
4. Sahle BW, Owen AJ, Mutowo MP, et al. Prevalence of heart failure in Australia: a systematic review. BMC Cardiovasc Disord. 2016 Feb 6;16:32.Texto completo Resumo
5. Norhammar A, Bodegard J, Vanderheyden M, et al. Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart. 2023 Mar 10;109(7):548-56.Texto completo Resumo
6. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-e913.Texto completo Resumo
7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Texto completo Resumo
8. Screever EM, van der Wal MHL, van Veldhuisen DJ, et al. Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol. 2023 Jan;112(1):123-33.Texto completo Resumo
9. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Texto completo Resumo
10. Kloner RA. Stunned and hibernating myocardium: where are we nearly 4 decades later? J Am Heart Assoc. 2020 Feb 4;9(3):e015502.Texto completo Resumo
11. Patel H, Madanieh R, Kosmas CE, et al. Reversible cardiomyopathies. Clin Med Insights Cardiol. 2015 May 21;9(Suppl 2):7-14.Texto completo Resumo
12. Bloom MW, Greenberg B, Jaarsma T, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017 Aug 24;3:17058. Resumo
13. Remes J, Reunanen A, Aromaa A, et al. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 1992 May;13(5):588-93. Resumo
14. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl 1):6-13A.Texto completo Resumo
15. Dunlay SM, Weston SA, Jacobsen SJ, et al. Risk factors for heart failure: a population-based case-control study. Am J Med. 2009 Nov;122(11):1023-8. Resumo
16. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001 Apr 9;161(7):996-1002.Texto completo Resumo
17. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998 Nov 24;98(21):2282-9. Resumo
18. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999 Feb 17;281(7):634-9. Resumo
19. Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 1999 Jun;106(6):605-12. Resumo
20. Kimmelstiel CD, Konstam MA. Heart failure in women. Cardiology. 1995;86(4):304-9. Resumo
21. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med. 2001 Mar;249(3):253-61.Texto completo Resumo
22. Lee MP, Glynn RJ, Schneeweiss S, et al. Risk factors for heart failure with preserved or reduced ejection fraction among medicare beneficiaries: application of competing risks analysis and gradient boosted model. Clin Epidemiol. 2020;12:607-16.Texto completo Resumo
23. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62. Resumo
24. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003 Jan 7;138(1):10-6. Resumo
25. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol. 2000 Jul;36(1):130-8.Texto completo Resumo
26. Kario K, Hoshide S, Mizuno H, et al; JAMP Study Group. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation. 2020 Nov 10;142(19):1810-20.Texto completo Resumo
27. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996 May 1;77(11):1017-20. Resumo
28. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34. Resumo
29. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 Jun 5;103(22):2668-73.Texto completo Resumo
30. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022 Jul 7;45(7):1670-90.Texto completo Resumo
31. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994 Aug;72(2 Suppl):S3-9.Texto completo Resumo
32. Schillaci G, Vaudo G, Reboldi G, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 2001 Dec;19(12):2265-70. Resumo
33. Horio T, Miyazato J, Kamide K, et al. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):938-44. Resumo
34. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 Dec;3(4):249-54. Resumo
35. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6. Resumo
36. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000 May;35(6):1628-37.Texto completo Resumo
37. Stolfo D, Uijl A, Vedin O, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. JACC Heart Fail. 2019 Jun;7(6):505-15.Texto completo Resumo
38. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-1010.Texto completo Resumo
39. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305-13.Texto completo Resumo
40. Ebong IA, Goff DC Jr, Rodriguez CJ, et al. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014 Nov-Dec;8(6):e540-8. Resumo
41. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987 Jan;9(1):184-8.Texto completo Resumo
42. Nousiainen T, Vanninen E, Jantunen E, et al. Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study. Leuk Lymphoma. 2002 Sep;43(9):1807-11. Resumo
43. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.Texto completo Resumo
44. Gottlieb SL, Edmiston WA J., Haywood LJ. Late, late doxorubicin cardiotoxicity. Chest. 1980 Dec;78(6):880-2. Resumo
45. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al; ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-801.Texto completo Resumo
46. Larsen CM, Garcia Arango M, Dasari H, et al. Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010. JAMA Netw Open. 2023 Feb 1;6(2):e2254669.Texto completo Resumo
47. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009 Dec 8;339:b4606.Texto completo Resumo
48. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997 May 8;336(19):1350-5. Resumo
49. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol. 1987;10 (Suppl 6):S135-40. Resumo
50. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003 Apr 16;41(8):1364-72.Texto completo Resumo
51. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000 Mar 1;35(3):681-9.Texto completo Resumo
52. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999 Jun 14;159(11):1197-204. Resumo
53. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 1997 Jul 3;337(1):32-41. Resumo
54. Chaudhary BA, Ferguson DS, Speir WA, Jr. Pulmonary edema as a presenting feature of sleep apnea syndrome. Chest. 1982 Jul;82(1):122-4. Resumo
55. Fletcher EC, Proctor M, Yu J, et al. Pulmonary edema develops after recurrent obstructive apneas. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1688-96. Resumo
56. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001 Jan;163(1):19-25. Resumo
57. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-67.Texto completo Resumo
58. Li X, Xue Q, Wang M, et al. Adherence to a healthy sleep pattern and incident heart failure: a prospective study of 408 802 UK Biobank participants. Circulation. 2021 Jan 5;143(1):97-9.Texto completo Resumo
59. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003 Mar 12;289(10):1251-7.Texto completo Resumo
60. Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med. 1988 Mar;112(3):225-30. Resumo
61. Goldenberg SP, Zeldis SM. Fatal acute congestive heart failure in a patient with idiopathic hemochromatosis and cocaine use. Chest. 1987 Aug;92(2):374-5. Resumo
62. O'Keefe DD, Grantham RN, Beierholm EA, et al. Cocaine and the contractile response to catecholamines in right ventricular failure. Am J Physiol. 1977 Sep;233(3):H399-403. Resumo
63. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002 Oct 10;347(15):1135-42.Texto completo Resumo
64. Smit MD, Moes ML, Maass AH, et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail. 2012 Sep;14(9):1030-40.Texto completo Resumo
65. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575-82.Texto completo Resumo
66. Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013 Mar;34(11):816-29.Texto completo Resumo
67. Maeder MT, Khammy O, dos Remedios C, et al. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011 Jul 26;58(5):474-80.Texto completo Resumo
68. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998 Mar;274(3 Pt 2):R577-95. Resumo
69. Vasan RS, Sullivan LM, Roubenoff R, et al; Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003 Mar 25;107(11):1486-91.Texto completo Resumo
70. Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res. 2002 Apr 5;90(6):641-8. Resumo
71. Wang L, Ma W, Markovich R, et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998 Sep 7;83(5):516-22. Resumo
72. Vecchione C, Colella S, Fratta L, et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 2001 Jun;37(6):1480-5. Resumo
73. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003 Oct 21;139(8):642-8. Resumo
74. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 Feb 12;350(7):655-63.Texto completo Resumo
75. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003 Aug 26;108(8):977-82.Texto completo Resumo
76. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2001 Mar 15;37(4):1042-8.Texto completo Resumo
77. Purwowiyoto SL, Prawara AS. Metabolic syndrome and heart failure: mechanism and management. Med Pharm Rep. 2021 Jan;94(1):15-21.Texto completo Resumo
78. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.Texto completo Resumo
79. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023 Nov 14;148(20):1636-64.Texto completo Resumo
80. Upadhya B, Hegde S, Tannu M, et al. Preventing new-onset heart failure: Intervening at stage A. Am J Prev Cardiol. 2023 Dec;16:100609.Texto completo Resumo
81. Ding N, Shah AM, Blaha MJ, et al. Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction. J Am Coll Cardiol. 2022 Jun 14;79(23):2298-305.Texto completo Resumo
82. Kamimura D, Cain LR, Mentz RJ, et al. Cigarette smoking and incident heart failure: insights from the Jackson Heart Study. Circulation. 2018 Jun 12;137(24):2572-82.Texto completo Resumo
83. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989 Feb 16;320(7):409-15. Resumo
84. Rubin E, Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res. 1994 Feb;18(1):111-4. Resumo
85. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002 Feb 5;136(3):181-91. Resumo
86. Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018 Apr 14;391(10129):1513-23.Texto completo Resumo
87. Rasoul D, Ajay A, Abdullah A, et al. Alcohol and heart failure. Eur Cardiol. 2023 Dec 26;18:e65.Texto completo Resumo
88. He J, Ogden LG, Bazzano LA, et al. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey epidemiologic follow-up study. Arch Intern Med. 2002 Jul 22;162(14):1619-24. Resumo
89. Abramson J, Berger A, Krumholz HM, et al. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001 Jul 23;161(14):1725-30. Resumo
90. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001 Aug 13-27;161(15):1849-56. Resumo
91. Basile C, Parlati ALM, Paolillo S, et al. Depression in heart failure with reduced ejection fraction, an undervalued comorbidity: an up-to-date review. Medicina (Kaunas). 2023 May 15;59(5):948.Texto completo Resumo
92. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421-6.Texto completo Resumo
93. Mujaj B, Zhang ZY, Yang WY, et al. Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Fail. 2022 Feb;9(1):685-94.Texto completo Resumo
94. Bomer N, Pavez-Giani MG, Grote Beverborg N, et al. Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism? J Intern Med. 2022 Jun;291(6):713-31.Texto completo Resumo
95. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-646.Texto completo Resumo
96. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022 Aug 2;146(5):e18-43.Texto completo Resumo
97. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009 Mar;30(6):679-88.Texto completo Resumo
98. Strandberg TE, Holme I, Faergeman O, et al. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol. 2009 May 15;103(10):1381-5. Resumo
99. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: behavioral counseling interventions. Nov 2020 [internet publication].Texto completo
100. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: behavioral counseling interventions. Jul 2022 [internet publication].Texto completo
101. Jurgens CY, Lee CS, Aycock DM, et al. State of the science: the relevance of symptoms in cardiovascular disease and research: a scientific statement from the American Heart Association. Circulation. 2022 Sep 20;146(12):e173-84.Texto completo Resumo
102. Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018 Jan 16;137(3):286-97.Texto completo Resumo
103. Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018 Aug 17;123(5):614-29.Texto completo Resumo
104. Asferg C, Usinger L, Kristensen TS, et al. Accuracy of multi-slice computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis. Eur J Radiol. 2012 May;81(5):e757-62. Resumo
105. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000 Apr 1;355(9210):1126-30. Resumo
106. Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005 Nov;26(21):2277-84.Texto completo Resumo
107. Tschope C, Kasner M, Westermann D, et al. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail. 2005 Jun;11(5 Suppl):S28-33. Resumo
108. Maisel A. The coming of age of natriuretic peptides: the emperor does have clothes! J Am Coll Cardiol. 2006 Jan 3;47(1):61-4.Texto completo Resumo
109. Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone. 2005;7 (Suppl 1):S7-17. Resumo
110. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004 Jun;147(6):1078-84. Resumo
111. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006 May 22;166(10):1081-7. Resumo
112. Mueller C, Laule-Kilian K, Scholer A, et al. Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol. 2004 Dec 15;94(12):1510-4. Resumo
113. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb 12;350(7):647-54.Texto completo Resumo
114. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004 May 5;43(9):1590-5.Texto completo Resumo
115. Wang TJ, Larson MG, Keyes MJ, et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007 Mar 20;115(11):1345-53.Texto completo Resumo
116. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004 Feb 10;109(5):594-600.Texto completo Resumo
117. Quinn B, Doyle B, McInerney J. Postnatal pre-cordial pain. Pulmonary embolism or peripartum cardiomyopathy. Emerg Med J. 2004 Nov;21(6):746-7.Texto completo Resumo
118. Chop WM Jr. Extending the New York Heart Association classification system. JAMA. 1985 Jul 26;254(4):505. Resumo
119. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 Nov;20(11):1505-35.Texto completo Resumo
120. Nakamura M, Tanaka F, Sato K, et al. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail. 2005 Dec;11(9):705-12. Resumo
121. Valle R, Aspromonte N, Barro S, et al. The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail. 2005 Jun;7(4):542-51.Texto completo Resumo
122. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. Sep 2018 [internet publication].Texto completo
123. Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle modifications for preventing and treating heart failure. J Am Coll Cardiol. 2018 Nov 6;72(19):2391-405.Texto completo Resumo
124. Ades PA, Keteyian SJ, Balady GJ, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail. 2013 Dec;1(6):540-7.Texto completo Resumo
125. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019 Jan 29;1(1):CD003331.Texto completo Resumo
126. Chen Z, Li M, Yin C, et al. Effects of cardiac rehabilitation on elderly patients with chronic heart failure: a meta-analysis and systematic review. PLoS One. 2022;17(8):e0273251.Texto completo Resumo
127. Tegegne TK, Rawstorn JC, Nourse RA, et al. Effects of exercise-based cardiac rehabilitation delivery modes on exercise capacity and health-related quality of life in heart failure: a systematic review and network meta-analysis. Open Heart. 2022 Jun;9(1):e001949.Texto completo Resumo
128. Dallas K, Dinas PC, Chryssanthopoulos C, et al. The effects of exercise on VO(2)peak, quality of life and hospitalization in heart failure patients: a systematic review with meta-analyses. Eur J Sport Sci. 2021 Sep;21(9):1337-50.Texto completo Resumo
129. Bjarnason-Wehrens B, Nebel R, Jensen K, et al. Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis. Eur J Prev Cardiol. 2020 Jun;27(9):929-52.Texto completo Resumo
130. Gomes-Neto M, Durães AR, Conceição LSR, et al. Effect of combined aerobic and resistance training on peak oxygen consumption, muscle strength and health-related quality of life in patients with heart failure with reduced left ventricular ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2019 Oct 15;293:165-75. Resumo
131. Taylor RS, Dalal HM, Zwisler AD. Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care? Eur Heart J. 2023 May 1;44(17):1511-8.Texto completo Resumo
132. Paluch AE, Boyer WR, Franklin BA, et al. Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: a scientific statement from the American Heart Association. Circulation. 2024 Jan 16;149(3):e217-e231.Texto completo Resumo
133. Thomas RJ, Beatty AL, Beckie TM, et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019 Jul 2;140(1):e69-e89.Texto completo Resumo
134. McDonagh ST, Dalal H, Moore S, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023 Oct 27;10(10):CD007130.Texto completo Resumo
135. Golbus JR, Lopez-Jimenez F, Barac A, et al. Digital technologies in cardiac rehabilitation: a science advisory from the American Heart Association. Circulation. 2023 Jul 4;148(1):95-107.Texto completo Resumo
136. Ezekowitz JA, Colin-Ramirez E, Ross H, et al; SODIUM-HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022 Apr 9;399(10333):1391-400. Resumo
137. Singh S, Goel S, Duhan S, et al. Effect of furosemide versus torsemide on hospitalizations and mortality in patients with heart failure: a meta-analysis of randomized controlled trials. Am J Cardiol. 2023 Nov 1;206:42-48. Resumo
138. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004.Texto completo Resumo
139. Gao J, Zhao C, Zhang WZ, et al. Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2023 Jul;28(4):905-23.Texto completo Resumo
140. Zhang H, Huetteman AT, Reyes EA, et al. Effects of sacubitril-valsartan in patients with various types of heart failure: a meta-analysis. J Cardiovasc Pharmacol. 2023 Jun 1;81(6):434-44.Texto completo Resumo
141. Rahhal A, Kasem M, Orabi B, et al. Effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction using real-world data: an updated systematic review and meta-analysis. Curr Probl Cardiol. 2023 Jan;48(1):101412.Texto completo Resumo
142. Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018 Jun 1;3(6):498-505.Texto completo Resumo
143. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Texto completo Resumo
144. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta-blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013 Jan 16;346:f55.Texto completo Resumo
145. Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017 Jun 20;69(24):2885-96.Texto completo Resumo
146. Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail. 2017 Feb;5(2):99-106.Texto completo Resumo
147. Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003040.Texto completo Resumo
148. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004 Nov 2;141(9):693-704. [Erratum in: Ann Intern Med. 2005 Mar 1;42(5):391.] Resumo
149. Pitt B, Bakris G, Ruilope LM, et al; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14;118(16):1643-50.Texto completo Resumo
150. Verma S, Dhingra NK, Butler J, et al; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. Resumo
151. National Institute for Health and Care Excellence. Empagliflozin for treating chronic heart failure with reduced ejection fraction. Mar 2022 [internet publication].Texto completo
152. National Institute for Health and Care Excellence. Dapagliflozin for treating chronic heart failure with reduced ejection fraction. Feb 2021 [internet publication].Texto completo
153. National Institute for Helath and Care Excellence. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. June 2023 [internet publication].Texto completo
154. National Institute for Health and Care Excellence. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. November 2023 [internet publication].Texto completo
155. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.Texto completo Resumo
156. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 Oct 8;383(15):1413-24.Texto completo Resumo
157. Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020 Apr 14;323(14):1353-68.Texto completo Resumo
158. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020 Jul 1;41(25):2379-92.Texto completo Resumo
159. Berg DD, Jhund PS, Docherty KF, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021 May 1;6(5):499-507.Texto completo Resumo
160. Docherty KF, Jhund PS, Claggett B, et al; DAPA-HF Investigators and Committees. Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiol. 2021 Nov 1;6(11):1298-305.Texto completo Resumo
161. Oyama K, Raz I, Cahn A, et al. Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022 Sep 1;7(9):914-23. Resumo
162. Butt JH, Dewan P, Merkely B, et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF Trial. Ann Intern Med. 2022 Jun;175(6):820-30. Resumo
163. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial. Circulation. 2021 Jan 26;143(4):326-36.Texto completo Resumo
164. Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309.Texto completo Resumo
165. Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022 Sep 21;43(36):3435-46.Texto completo Resumo
166. McDowell K, Welsh P, Docherty KF, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022 Jun;24(6):1066-76.Texto completo Resumo
167. Ferreira JP, Zannad F, Butler J, et al. Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-Pooled. JAMA Cardiol. 2022 Nov 1;7(11):1148-59.Texto completo Resumo
168. Butler J, Packer M, Siddiqi TJ, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol. 2023 May 16;81(19):1902-14.Texto completo Resumo
169. Packer M, Butler J, Zeller C, et al. Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure. Circulation. 2023 Sep 26;148(13):1011-22.Texto completo Resumo
170. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Sep 22;387(12):1089-98. Resumo
171. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022 Oct 4;80(14):1302-10.Texto completo Resumo
172. Vaduganathan M, Claggett BL, Jhund P, et al. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2022 Dec 1;7(12):1259-63.Texto completo Resumo
173. Desai AS, Jhund PS, Claggett BL, et al. Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-34.Texto completo Resumo
174. Mc Causland FR, Claggett BL, Vaduganathan M, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2023 Jan 1;8(1):56-65. Resumo
175. Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022 Dec;10(12):869-81. Resumo
176. Yang M, Butt JH, Kondo T, et al. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. Eur J Heart Fail. 2022 Dec;24(12):2307-19.Texto completo Resumo
177. Jhund PS, Claggett BL, Talebi A, et al. Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER Trial. JAMA Cardiol. 2023 Jun 1;8(6):554-63.Texto completo Resumo
178. Kondo T, Jering KS, Borleffs CJW, et al. Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2023 Apr 4;147(14):1067-78.Texto completo Resumo
179. Chatur S, Vaduganathan M, Claggett BL, et al. Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER Trial. Circulation. 2023 Nov 28;148(22):1735-45.Texto completo Resumo
180. Chatur S, Vaduganathan M, Claggett B, et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J. 2023 Aug 14;44(31):2930-43.Texto completo Resumo
181. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2023 Feb 7;81(5):460-73.Texto completo Resumo
182. Peikert A, Chandra A, Kosiborod MN, et al. Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the DELIVER Trial. JAMA Cardiol. 2023 Jul 1;8(7):684-90.Texto completo Resumo
183. Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER Trial. Circulation. 2022 Oct 18;146(16):1210-24.Texto completo Resumo
184. Wang X, Vaduganathan M, Claggett BL, et al. Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA-HF and DELIVER. Circulation. 2022 Nov 7 [Epub ahead of print]. Resumo
185. Butt JH, Docherty KF, Claggett BL, et al. Association of dapagliflozin use with clinical outcomes and the introduction of uric acid-lowering therapy and colchicine in patients with heart failure with and without gout: a patient-level pooled meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023 Apr 1;8(4):386-93.Texto completo Resumo
186. Nassif ME, Windsor SL, Gosch K, et al. Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials. Circ Heart Fail. 2023 Jul;16(7):e009837.Texto completo Resumo
187. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep 3;400(10354):757-67. Resumo
188. Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100933.Texto completo Resumo
189. Tsai WC, Hsu SP, Chiu YL, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022 Oct 14;12(10):e060655.Texto completo Resumo
190. Banerjee M, Pal R, Nair K, et al. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis. Indian Heart J. 2023 Mar-Apr;75(2):122-7.Texto completo Resumo
191. Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023 Jun 27;81(25):2377-87. Resumo
192. Wang Y, Gao T, Meng C, et al. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Eur J Med Res. 2022 Dec 29;27(1):314.Texto completo Resumo
193. Rasalam R, Atherton JJ, Deed G, et al. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Fail. 2021 Oct;8(5):4093-118.Texto completo Resumo
194. Shrestha DB, Budhathoki P, Sedhai YR, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure. J Cardiovasc Pharmacol. 2021 Oct 1;78(4):501-14. Resumo
195. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-29. Resumo
196. Zhao L, Guo W, Huang W, et al. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. Diabetes Res Clin Pract. 2022 May;187:109871.Texto completo Resumo
197. Gupta K, Spertus JA, Birmingham M, et al. Racial differences in quality of life in patients with heart failure treated with sodium-glucose cotransporter 2 inhibitors: a patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials. Circulation. 2023 Jul 18;148(3):220-8.Texto completo Resumo
198. Vukadinović D, Abdin A, Anker SD, et al. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022 Sep;24(9):1625-32.Texto completo Resumo
199. Carson P, Ziesche S, Johnson G, et al; Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999 Sep;5(3):178-87. Resumo
200. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049-57.Texto completo Resumo
201. Bryan Richard S, Huang B, Liu G, et al. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials. Clin Cardiol. 2021 Apr;44(4):463-71.Texto completo Resumo
202. Benstoem C, Kalvelage C, Breuer T, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev. 2020 Nov 4;11(11):CD013004.Texto completo Resumo
203. Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 Jun 19;358(25):2667-77.Texto completo Resumo
204. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013 May;15(5):551-9.Texto completo Resumo
205. Vamos M, Erath JW, Hohnloser SH, et al. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015 Jul 21;36(28):1831-8.Texto completo Resumo
206. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015 Aug 30;351:h4451.Texto completo Resumo
207. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37.Texto completo Resumo
208. Jarcho JA. Biventricular pacing. N Engl J Med. 2006 Jul 20;355(3):288-94. Resumo
209. Witt CM, Wu G, Yang D, et al. Outcomes with left bundle branch block and mildly to moderately reduced left ventricular function. JACC Heart Fail. 2016 Nov;4(11):897-903.Texto completo Resumo
210. Bristow MR, Saxon LA, Boehmer J, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.Texto completo Resumo
211. De Marco T, Wolfel E, Feldman AM, et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb;14(1):9-18. Resumo
212. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2;52(23):1834-43.Texto completo Resumo
213. Mark DB, Anstrom KJ, Sun JL, et al; Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008 Sep 4;359(10):999-1008.Texto completo Resumo
214. Bertoldi EG, Polanczyk CA, Cunha V, et al. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? J Card Fail. 2011 Oct;17(10):860-6. Resumo
215. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012 Jun;14(6):628-34.Texto completo Resumo
216. Cazeau S, Leclercq C, Lavergne T, et al; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001 Mar 22;344(12):873-80.Texto completo Resumo
217. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000 Dec 19;102(25):3053-9. Resumo
218. Abraham WT, Fisher WG, Smith AL, et al; MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13;346(24):1845-53.Texto completo Resumo
219. Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail. 2001 Aug;3(4):481-9.Texto completo Resumo
220. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006 Aug;27(16):1928-32.Texto completo Resumo
221. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005 Mar 2;7(2):243-51.Texto completo Resumo
222. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005 Dec;26(24):2681-8.Texto completo Resumo
223. Ellenbogen KA, Wood MA, Klein HU. Why should we care about CARE-HF? J Am Coll Cardiol. 2005 Dec 20;46(12):2199-203.Texto completo Resumo
224. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006 Jul 4;114(1):18-25.Texto completo Resumo
225. Cleland JG, Daubert JC, Erdmann E, et al. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail. 2005 Mar 2;7(2):205-14.Texto completo Resumo
226. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49.Texto completo Resumo
227. Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009 Mar;157(3):457-66. Resumo
228. Ghio S, Freemantle N, Scelsi L, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009 May;11(5):480-8.Texto completo Resumo
229. Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response: a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol. 2008 Aug 5;52(6):438-45.Texto completo Resumo
230. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16;115(2):204-12.Texto completo Resumo
231. Daubert C, Gold MR, Abraham WT, et al; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10;54(20):1837-46.Texto completo Resumo
232. Linde C, Gold MR, Abraham WT, et al. REVERSE study: CRT produces long-term improvements in disease progression in mildly symptomatic heart failure patients. Five-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction study. Paper presented at: European Society of Cardiology Congress 2012. 27 August 2012. Munich, Germany.
233. Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023 Sep;20(9):e17-e91.Texto completo Resumo
234. Morris AA, Khazanie P, Drazner MH, et al. Guidance for timely and appropriate referral of patients with advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2021 Oct 12;144(15):e238-e250.Texto completo Resumo
235. "I Need Help" - a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017 May;36(5):593-4. Resumo
236. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection. A scientific statement from the American Heart Association. Circulation. 2012 Nov 27;126(22):2648-67.Texto completo Resumo
237. Gopinathannair R, Cornwell WK, Dukes JW, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation. 2019 May 14;139(20):e967-89.Texto completo Resumo
238. Cook JL, Colvin M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: ambulatory and community patient care: a scientific statement from the American Heart Association. Circulation. 2017 Jun 20;135(25):e1145-58.Texto completo Resumo
239. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018 Jan;20(1):125-33.Texto completo Resumo
240. Hamza M, Sattar Y, Manasrah N, et al. Meta-analysis of efficacy and safety of intravenous iron in patients with iron deficiency and heart failure with reduced ejection fraction. Am J Cardiol. 2023 Sep 1;202:119-30. Resumo
241. Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023 Dec 21;44(48):5077-91.Texto completo Resumo
242. Kalra PR, Cleland JGF, Petrie MC, et al; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2023 Dec 17;400(10369):2199-209.Texto completo Resumo
243. Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023 Sep 14;389(11):975-86.Texto completo Resumo
244. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017 May 16;317(19):1958-66.Texto completo Resumo
245. Lunney M, Ruospo M, Natale P, et al. Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466.Texto completo Resumo
246. Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. Eur Cardiol. 2022 Feb;17:e17.Texto completo Resumo
247. Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc. 1999 Mar;47(3):302-8. Resumo
248. Risler T, Schwab A, Kramer B, et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994;84 (Suppl 2):155-61. Resumo
249. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13. Resumo
250. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25.Texto completo Resumo
251. Triposkiadis F, Giamouzis G, Kelepeshis G, et al. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther. 2007 Feb;45(2):71-7. Resumo
252. Zwisler AD, Soja AM, Rasmussen S, et al. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. Am Heart J. 2008 Jun;155(6):1106-13. Resumo
253. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987 Sep 26;2(8561):709-11. Resumo
254. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981 Feb;70(2):234-9. Resumo
255. National Institute for Health and Care Excellence. Ivabradine for treating chronic heart failure. Nov 2012 [internet publication].Texto completo
256. Fogelman AM, La Mont JT, Finkelstein S, et al. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients. Lancet. 1971 Oct 2;2(7727):727-9. Resumo
257. Ingelfinger JA, Goldman P. The serum digitalis concentration - does it diagnose digitalis toxicity? N Engl J Med. 1976 Apr 15;294(16):867-70. Resumo
258. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974 Jul;57(1):63-8. Resumo
259. Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016 Nov;21(6):645-60.Texto completo Resumo
260. Coats AJS, Abraham WT, Zile MR, et al. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022 Sep;24(9):1665-73.Texto completo Resumo
261. Molina-Linde JM, Cordero-Pereda D, Baños-Álvarez E, et al. Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review. ESC Heart Fail. 2023 Oct;10(5):2760-72.Texto completo Resumo
262. Gin J, Chow CL, Voskoboinik A, et al. Improved outcomes of conduction system pacing in heart failure with reduced ejection fraction: a systematic review and meta-analysis. Heart Rhythm. 2023 Aug;20(8):1178-87. Resumo
263. Sánchez LA, Guerrero-Beltrán CE, Cordero-Reyes AM, et al. Use of stem cells in heart failure treatment: where we stand and where we are going. Methodist Debakey Cardiovasc J. 2013 Oct-Dec;9(4):195-200.Texto completo Resumo
264. Chowdhury MA, Zhang JJ, Rizk R, et al. Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence. Front Physiol. 2023;14:1344885.Texto completo Resumo
265. Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016 Dec 24;(12):CD007888.Texto completo Resumo
266. Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure. Circ Res. 2012 Mar 2;110(5):777-93.Texto completo Resumo
267. Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016 May 1;1(2):163-71.Texto completo Resumo
268. Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016 Mar 19;387(10024):1178-86. Resumo
269. Klein P, Bax JJ, Shaw LJ, et al. Early and late outcome of left ventricular reconstruction surgery in ischemic heart disease. Eur J Cardiothorac Surg. 2008 Dec;34(6):1149-57.Texto completo Resumo
270. Bolling SF, Pagani FD, Deeb GM, et al. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998 Feb;115(2):381-8.Texto completo Resumo
271. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005 Feb 1;45(3):381-7.Texto completo Resumo
272. Athanasuleas CL, Stanley AW, Jr., Buckberg GD, et al; RESTORE Group. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol. 2001 Apr;37(5):1199-209.Texto completo Resumo
273. Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021 Jan 14;384(2):105-16.Texto completo Resumo
274. Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 Jul 13;78(2):97-108.Texto completo Resumo
275. Felker GM, Solomon SD, Claggett B, et al. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 2022 Jan 1;7(1):26-34.Texto completo Resumo
276. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003 Dec 1;92(11):1350-4. Resumo
277. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997 Jun 17;95(12):2660-7. Resumo
278. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar 21;113(11):1424-33.Texto completo Resumo
279. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003 Nov 19;290(19):2581-7.Texto completo Resumo
280. Fonarow GC, Adams KF, Jr., Abraham WT, et al; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005 Feb 2;293(5):572-80.Texto completo Resumo
281. Brophy JM, Dagenais GR, McSherry F, et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004 Mar 1;116(5):300-4. Resumo
282. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant. 2004 Dec;23(12):1414-22. Resumo
283. Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009 Jan;95(1):56-62.Texto completo Resumo
284. Gerstein HC, Swedberg K, Carlsson J, et al; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008 Aug 11;168(15):1699-704.Texto completo Resumo
285. Castel MA, Magnani S, Mont L, et al. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace. 2010 Aug;12(8):1136-40.Texto completo Resumo
286. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007 Mar 27;115(12):1563-70.Texto completo Resumo
287. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019 Apr 16;139(16):e840-78.Texto completo Resumo
288. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980 Dec 18;303(25):1443-8. Resumo
289. Turini GA, Waeber B, Brunner HR. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. Eur Heart J. 1983 Jan;4 (Suppl A):189-97. Resumo
290. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999 Aug;138(2 Pt 1):285-90. Resumo
291. Alpert MA. Cardiovascular factors influencing survival in dialysis patients. Adv Perit Dial. 1996;12:110-9. Resumo
292. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584-90.Texto completo Resumo
293. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002 Jun 5;39(11):1780-6.Texto completo Resumo
294. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001 Oct;38(4):955-62.Texto completo Resumo
295. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000 Jun;35(7):1737-44.Texto completo Resumo
296. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80.Texto completo Resumo
297. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003 Jan 21;107(2):294-9.Texto completo Resumo
298. Ghali JK, Anand IS, Abraham WT, et al; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008 Jan 29;117(4):526-35.Texto completo Resumo
299. Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022 Nov 1;43(41):4362-73.Texto completo Resumo
300. Chow SL, Bozkurt B, Baker WL, et al. Complementary and alternative medicines in the management of heart failure: a scientific statement from the American Heart Association. Circulation. 2023 Jan 10;147(2):e4-30.Texto completo Resumo
301. Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014 Jun 14;35(23):1559-67.Texto completo Resumo
302. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017 Aug 22;318(8):713-20.Texto completo Resumo
303. Greene SJ, Butler J, Spertus JA, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. JAMA Cardiol. 2021 May 1;6(5):522-31.Texto completo Resumo
304. Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail. 2007 Feb;13(1):56-62. Resumo
305. Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ. 2007 May 5;334(7600):942.Texto completo Resumo
306. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev. 2015 Oct 31;(10):CD007228.Texto completo Resumo
307. Masterson Creber R, Dodson JA, Bidwell J, et al. Telehealth and Health Equity in Older Adults With Heart Failure: A Scientific Statement From the American Heart Association. Circ Cardiovasc Qual Outcomes. 2023 Nov;16(11):e000123.Texto completo Resumo
308. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 Sep 11;398(10304):991-1001. Resumo
309. Curtain JP, Lee MMY, McMurray JJ, et al. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart. 2023 May 15;109(11):823-31.Texto completo Resumo
310. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023 Jun 24;401(10394):2113-23. Resumo
311. McGee MJ, Ray M, Brienesse SC, et al. Remote monitoring in patients with heart failure with cardiac implantable electronic devices: a systematic review and meta-analysis. Open Heart. 2022 Nov;9(2):e002096.Texto completo Resumo
312. Alotaibi S, Hernandez-Montfort J, Ali OE, et al. Remote monitoring of implantable cardiac devices in heart failure patients: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2020 May;25(3):469-79. Resumo
313. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801.Texto completo Resumo
314. Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2024 Apr 16;83(15):1444-88.Texto completo
315. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal